0
Abstract: Slide Presentations |

Sleep Quality in Asthma: Results of a Large Prospective Clinical Trial FREE TO VIEW

John G. Mastronarde, MD*; Robert A. Wise, MD; Steven M. Scharf, MD, PhD; David M. Shade, JD; Christopher O. Olopade, MD
Author and Funding Information

The Ohio State University Medical Center, Columbus, OH


Chest


Chest. 2004;126(4_MeetingAbstracts):706S. doi:10.1378/chest.126.4_MeetingAbstracts.706S
Text Size: A A A
Published online

Abstract

PURPOSE:  Previous reports suggest asthmatics have an increase incidence of sleep disturbances and excessive daytime sleepiness. However, these studies have been limited due to reliance on population surveys or by small numbers of participants. We sought to directly measure sleep quality and daytime sleepiness in a cohort of well-characterized asthmatics participating in a prospective clinical trial.

METHODS:  Data were collected in sub-study of a large multi-center randomized double-masked controlled trial of mild-moderate asthmatics evaluating the effect of low dose theophylline on asthma control in comparison to montelukast and placebo. Each participant was administered sleep symptom questionnaires at randomization and at the final visit (6 months after randomization). These included the Pittsburgh Sleep Quality Questionnaire (PSQI) and the Epworth Sleep Scale (ESS). Sleep questionnaire treatment group differences were analyzed using Wilcoxon rank-sum tests due to non-normality of the responses.

RESULTS:  Data were available for 487 participants. Baseline mean values were: age 40 + 15, 74% female, FEV1 79 +16 percent predicted, Juniper Asthma Control Questionnaire score 2.35 + 0.63, PSQI 7.8 +4, and ESS 8.5+4.9 (39% with ESS > 10). Insomnia was reported by 45% of participants. There were no significant differences in the PSQI, ESS, or reported incidence of insomnia between the three treatment groups. There were significant correlations between the Juniper score and PSQI (r2 = .215; p=.0000), and ESS (r2 = .035; p = .0003), but not between either ESS or PSQI and FEV1. The incidence of patients with symptoms highly suggestive of sleep apnea (ESS >10 and snoring > 3 times a week was 9.2%.

CONCLUSION:  Asthmatics suffer significant sleep quality disturbances with a resultant increase in daytime sleepiness.

CLINICAL IMPLICATIONS:  Sleep disturbances are common in asthmatics and may adversely affect their quality of life. Further, sleep related symptoms are predictors of disease-specific indices of quality of life. Clinicians caring for asthmatics should incorporate objective measures of sleep disturbances in their routine care of these patients.

DISCLOSURE:  J.G. Mastronarde, None.

Monday, October 25, 2004

10:30 AM- 12:00 PM


Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

CHEST Journal Articles
Salmeterol vs Theophylline*: Sleep and Efficacy Outcomes in Patients With Nocturnal Asthma
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543